Last update Feb. 19, 2019
Likely Compatibility
We do not have alternatives for غانودوتروفين كوريونيك.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
غانودوتروفين كوريونيك is Human Chorionic Gonadotrophin in Arabic.
Is written in other languages:غانودوتروفين كوريونيك is also known as
غانودوتروفين كوريونيك belongs to this group or family:
Main tradenames from several countries containing غانودوتروفين كوريونيك in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 37.900 | daltons |
Tmax | 6 - 20 | hours |
T½ | 6 - 38 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a glycoprotein hormone, produced initially by the embryo and then by the placenta, obtained from the urine of pregnant women and composed of 2 subunits: alpha (smaller) and beta (larger); the latter confers specificity.
Administered via subcutaneous and intramuscular injection. Subcutaneous administration produces peak levels and later elimination.
Its effects are mainly those of the luteinizing hormone, responsible for triggering ovulation and the formation of the corpus luteum of the ovary in women and stimulating its hormonal production especially at the beginning of pregnancy (Sygma-Aldrich 2016).
Indicated to stimulate ovulation in assisted reproduction techniques. It is also used in threatened miscarriage and in cryptorchidism in children.
It is found naturally in small amounts in breastmilk (Lawrence 2016 p.139-147)
Since the last update we have not found published data on its excretion in breastmilk.
Its high molecular weight makes it very unlikely it will transfer into milk in significant quantities.
Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.
May cause increased prolactin and galactorrhea (Mendes 2001).
No adverse effects have been reported in infants.
In infertility treatments, the possible theoretical anovulatory effect of frequent on demand breastfeeding must be taken into account.
See below the information of these related products: